On Thursday Pfizer Inc. (NYSE: PFE) announced the European Medicines Agency (EMA) has adopted a negative opinion for XELJANZ® (tofacitinib ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE